Lonza buys Genentech facility for $1.2B to boost commercial biologics manufacturing

With Lonza anticipating persistent increase in demand for commercial biologics manufacturing, the Swiss company is picking up a production site owned by Roche’s Genentech for $1.2 billion in cash.

The manufacturer also has CHF 500 million ($562.5 million) in its budget to upgrade the Vacaville, CA, facility to support large-scale biologics production for mammalian drug substances. The site has about 750 Genentech workers, who will be offered employment by the manufacturer.

According to Lonza, the Vacaville site is one of the biggest biologics production facilities in the world in terms of volume. At present, the facility has approximately 330,000 liters of bioreactor capacity, in 12,000-liter and 25,000-liter reactor sizes.

The purchase is expected to be completed in the second half of the year. “Roche products currently manufactured at the site will be supplied by Lonza, with committed volumes over the medium term, phasing out as the site transitions to serve…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks